Claire holds a PhD in biochemistry and has led organisations that advocate for commercial delivery of science for 25 years, starting within the Cambridge UK biotechnology cluster. She has worked to champion biotechnology across sectors with leadership roles in the Council of European BioRegions, European Biotechnology Network and Nanotechnology Industries Association. She joined EuropaBio in 2020 and in addition to her current role as Director General, she is also a Governing Board Member for the Innovative Health Initiative (IHI) and Board Member of W@ LifeSciences.
- How will the new biotech act impact Europe?
- What difference will this make in light of the Critical Medicines Act?